GS-5745 is a monoclonal antibody that may help reduce inflammation in the lungs, leading to improved lung function in people with cystic fibrosis (CF).1
How GS-5745 works
GS-5745 inhibits matrix metalloproteinase 9 (MMP-9) — an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis — and has antineoplastic potential. Once administered, GS-5745 binds to MMP-9 and inhibits its enzymatic activity. This prevents extracellular matrix protein degradation and, potentially, blocks tumor growth, invasion, and metastasis. MMP-9 plays an important role in the degradation of collagens and proteoglycans, and increased MMP-9 activity has been linked to increased invasion and cancer metastasis.2
Preclinical studies showed that blocking MMP-9 alters the tumor microenvironment, and it is associated with greater chemotherapy penetration and improved anti-tumor immunity.3
A Phase 2 study to evaluate the effect of GS-5745 on FEV1 (forced expiration in one second, a measure of lung health) in adults with cystic fibrosis (NCT02759562) is recruiting participants. The study will evaluate GS-5745’s effect on pre-bronchodilator FEV1 in adults with CF after eight weeks of treatment. There will be two parts to the study: In the first, GS-5745 at 600 mg or placebo will be administered for eight weeks. In the second, GS-5745 at 300 mg, 150 mg, or placebo will be administered for eight weeks. Part 2 will be initiated once Part 1 is completed.
Its primary goal is absolute change in pre-bronchodilator FEV1 percent predicted, as measured from baseline to week eight.
The study is expected to be completed in March 2019.
Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.